Cancer and Epigenetics

  • Bae, Jae-Bum (Department of Biochemistry, Genome Regulation Center, Yonsei University) ;
  • Kim, Young-Joon (Department of Biochemistry, Genome Regulation Center, Yonsei University)
  • Published : 2008.09.30

Abstract

One of the interesting trends in genome research is the study about epigenetic modification above single gene level. Epigenetics refers study about heritable change in the genome, which accompany modification in DNA or Chromatin besides DNA sequence alteration. We used to have the idea that the coding potential of the genome lies within the arrangement of the four bases A, T, G, C; However, additional information that affects phenotype is stored in the distribution of the modified base 5-methylcytosine. This form of information storage is flexible enough to be adapted for different somatic cell types, yet is stable enough to be retained during mitosis and/or meiosis. Epigenetic modification is a modification of the genome, as opposed to being part of the genome, so is known as "epigenetics"(Greek for "upon" genetics). This modification could be methylation on Cytosine base or post translational modification on histone protein(methylation, acetylation, phosphorylation, Sumoylation)($Dimitrijevi\hat{E}$ et al 2005). In this review, we would like to focus on the relationship of DNA methylation and cancer.

Keywords

References

  1. Ballestar E and Wolffe AP (2001) Methyl-CpG-binding proteins. Targeting specific gene repression Eur J Biochem 268(1): 1-6. https://doi.org/10.1046/j.1432-1327.2001.01869.x
  2. Buschausen G, Wittig B, Graessmann M, and Graessmann A (1987) Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinasegene. Proc Natl Acad Sci USA 84: 1177-1181.
  3. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C, and Weiss G (2007) Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177(5): 1753-8. https://doi.org/10.1016/j.juro.2007.01.010
  4. Curradi M, Izzo A,Badaracco G, and Landsberge N (2002) Molecular Mechanisms of Gene Silencing Mediated by DNA Methylation. Mol Cell Biol 3157-3173.
  5. Detich N, Theberge Y, and Szyf M (2002) Promoter-specific Activation and Demethylation by MBD2/Demethylase. J Biol Chem, 277( 39): 35791-35794, https://doi.org/10.1074/jbc.C200408200
  6. De Smet C, Loriot A, and Boon T (2004) Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5' Region of Gene MAGE-A1 in Tumor Cells. Mol Cell Biol
  7. Di Croce L, Raker VA, and Corsaro M (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079-1082. https://doi.org/10.1126/science.1065173
  8. DimitrijeviE D (2005) Cancer epigenome: A review Arch Oncol 13(3-4): 108-14. https://doi.org/10.2298/AOO0504108D
  9. Eden S and Cedar H (1994) Role of DNA methylation in the regulation of transcription. Curr Opin Genet Dev 4: 255-259. https://doi.org/10.1016/S0959-437X(05)80052-8
  10. Epigenomics Inc, www.epigenomics.com
  11. Gal-Yam EN, Saito Y, Egger G, and Jones PA (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59: 267-80. https://doi.org/10.1146/annurev.med.59.061606.095816
  12. Kass SU, Goddard JP, and Adams RL (1993) Inactive chromatin spreads from a focus of methylation. Mol Cell Biol 13: 7372- 7379. https://doi.org/10.1128/MCB.13.12.7372
  13. Kass SU, Landsberger N, and Wolffe PA (1997) DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol 7: 157-165. https://doi.org/10.1016/S0960-9822(97)70086-1
  14. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y,Huang TH, and Issa JP (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40: 741-750. https://doi.org/10.1038/ng.159
  15. Klose RJ and Bird AP (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 31: 89-97. https://doi.org/10.1016/j.tibs.2005.12.008
  16. Li E (1999) The mojo of methylation Nat Gen 23: 5-6 https://doi.org/10.1038/12595
  17. Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T, Meissner A, and Jaenisch R (2007) Dnmt3b promotes tumorigenesis in vivo by genespecific de novo methylation and transcriptional silencing. Gen Dev 21: 3110-3122. https://doi.org/10.1101/gad.1594007
  18. Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, and Ecker JR (2008) Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133(3): 523-36. https://doi.org/10.1016/j.cell.2008.03.029
  19. Lofton-Day C, Model F, DeVos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grutzmann R, Pilarsky C, and Sledziewski A (2008) Diagnostics and Genetics. DNA methylation Biomarkers for Blood based Colorectal Cancer screening.Clin Chem 54: 414- 423. https://doi.org/10.1373/clinchem.2007.095992
  20. Partha DM and Singal R (2004) DNA Methylation and Cancer Jour Clin Onco 22( 22): 4632-4642. https://doi.org/10.1200/JCO.2004.07.151
  21. Patra SK, Patra A, Rizzi F, Ghosh TC, and Bettuzzi S (2008) Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer Dev 27(2): 315-34. https://doi.org/10.1007/s10555-008-9118-y
  22. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, and Jones PA (2004) Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation Mol Can Res 2: 62- 72.
  23. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, and Laird PW (2004) Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen. Cancer Research 64: 3807-381. https://doi.org/10.1158/0008-5472.CAN-03-3852
  24. Zochbauer-Muller S, Minna JD, and Gazdar AF (2002) Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications. The Oncologist, 7(5): 451-457. https://doi.org/10.1634/theoncologist.7-5-451